CLINICAL TRIALS PROFILE FOR ZOLADEX

All Clinical Trials for ZOLADEX

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002597 ↗	Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer	Completed	National Cancer Institute (NCI)	Phase 3	1994-10-01	RATIONALE: Radiation therapy (RT) uses high-energy x-rays to damage tumor cells. Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using flutamide, goserelin, and leuprolide may fight prostate cancer by reducing the production of androgens. It is not yet known which regimen of antiandrogen therapy is most effective for prostate cancer. PURPOSE: Randomized phase III trial to study the effectiveness of radiation therapy with or without antiandrogen therapy in treating patients who have stage I or stage II prostate cancer.
NCT00002597 ↗	Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer	Completed	Radiation Therapy Oncology Group	Phase 3	1994-10-01	RATIONALE: Radiation therapy (RT) uses high-energy x-rays to damage tumor cells. Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using flutamide, goserelin, and leuprolide may fight prostate cancer by reducing the production of androgens. It is not yet known which regimen of antiandrogen therapy is most effective for prostate cancer. PURPOSE: Randomized phase III trial to study the effectiveness of radiation therapy with or without antiandrogen therapy in treating patients who have stage I or stage II prostate cancer.
NCT00003645 ↗	Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence	Terminated	AstraZeneca	Phase 3	1999-06-14	RATIONALE: Testosterone can stimulate the growth of prostate cancer cells. Hormone therapy using leuprolide and flutamide may fight prostate cancer by reducing the production of testosterone. It is not yet known whether receiving leuprolide and flutamide is more effective than receiving no further therapy. PURPOSE: Randomized phase III trial to determine the effectiveness of hormone therapy in treating patients who have stage I or stage II prostate cancer that is at high risk of recurrence and who have already undergone surgery.
NCT00003645 ↗	Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence	Terminated	Eastern Cooperative Oncology Group	Phase 3	1999-06-14	RATIONALE: Testosterone can stimulate the growth of prostate cancer cells. Hormone therapy using leuprolide and flutamide may fight prostate cancer by reducing the production of testosterone. It is not yet known whether receiving leuprolide and flutamide is more effective than receiving no further therapy. PURPOSE: Randomized phase III trial to determine the effectiveness of hormone therapy in treating patients who have stage I or stage II prostate cancer that is at high risk of recurrence and who have already undergone surgery.
NCT00003645 ↗	Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence	Terminated	National Cancer Institute (NCI)	Phase 3	1999-06-14	RATIONALE: Testosterone can stimulate the growth of prostate cancer cells. Hormone therapy using leuprolide and flutamide may fight prostate cancer by reducing the production of testosterone. It is not yet known whether receiving leuprolide and flutamide is more effective than receiving no further therapy. PURPOSE: Randomized phase III trial to determine the effectiveness of hormone therapy in treating patients who have stage I or stage II prostate cancer that is at high risk of recurrence and who have already undergone surgery.
NCT00003645 ↗	Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence	Terminated	M.D. Anderson Cancer Center	Phase 3	1999-06-14	RATIONALE: Testosterone can stimulate the growth of prostate cancer cells. Hormone therapy using leuprolide and flutamide may fight prostate cancer by reducing the production of testosterone. It is not yet known whether receiving leuprolide and flutamide is more effective than receiving no further therapy. PURPOSE: Randomized phase III trial to determine the effectiveness of hormone therapy in treating patients who have stage I or stage II prostate cancer that is at high risk of recurrence and who have already undergone surgery.
NCT00003915 ↗	Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment	Completed	Dana-Farber Cancer Institute	Phase 2	2004-03-01	The purpose of this study is to see if the combination of chemotherapy drugs and drugs to suppress testosterone (hormone therapy) is effective in controlling early prostate cancer. This study will attempt to: - stop or slow the growth of disease - gain information about prostate cancer - evaluate the effectiveness and side effects of the study drug

Clinical Trial Conditions for ZOLADEX

Condition Name

Condition Name for ZOLADEX
Intervention	Trials
Prostate Cancer	57
Breast Cancer	28
Prostate Adenocarcinoma	11
Stage III Prostate Cancer	8

Condition MeSH

Condition MeSH for ZOLADEX
Intervention	Trials
Prostatic Neoplasms	87
Breast Neoplasms	48
Adenocarcinoma	21
Carcinoma	5

Clinical Trial Locations for ZOLADEX

Trials by Country

Trials by Country for ZOLADEX
Location	Trials
United States	624
Canada	39
China	25
United Kingdom	15
Japan	12

Trials by US State

Trials by US State for ZOLADEX
Location	Trials
California	31
Texas	29
Massachusetts	23
Maryland	23
Illinois	19

Clinical Trial Progress for ZOLADEX

Clinical Trial Phase

Clinical Trial Phase for ZOLADEX
Clinical Trial Phase	Trials
PHASE2	2
PHASE1	2
Phase 4	11

Clinical Trial Status

Clinical Trial Status for ZOLADEX
Clinical Trial Phase	Trials
Completed	63
RECRUITING	25
Active, not recruiting	20

Clinical Trial Sponsors for ZOLADEX

Sponsor Name

Sponsor Name for ZOLADEX
Sponsor	Trials
National Cancer Institute (NCI)	36
AstraZeneca	17
M.D. Anderson Cancer Center	9

Sponsor Type

Sponsor Type for ZOLADEX
Sponsor	Trials
Other	171
Industry	80
NIH	40

ZOLADEX Market Analysis and Financial Projection

Last updated: April 25, 2026

Zoladex (goserelin) Clinical Trials Update, Market Analysis, and Projection (2024-2035)

What is Zoladex and who uses it?

Zoladex is a long-acting gonadotropin-releasing hormone (GnRH) agonist (goserelin) delivered as an implant (commonly 3.6 mg monthly and 10.8 mg every 12 weeks formulations) used to treat hormone-sensitive conditions, most notably:

• Prostate cancer (advanced hormone-dependent prostate cancer; also used in combination treatment contexts depending on region/label)
• Breast cancer in selected pre-/perimenopausal or hormone-receptor–driven settings based on local labeling
• Endometriosis and uterine fibroids (where approved)

Market activity centers on ongoing maintenance prescriptions, aging demographics in major markets, and line-of-therapy selection where GnRH agonists remain standard-of-care in specific clinical pathways.

---

What is the clinical trials update for Zoladex?

Active interventional trial activity for Zoladex is limited in recent public registries, with most current evidence being label-supporting and maintenance of standard-of-care use rather than frequent new phase programs. Public clinical trial activity tends to cluster around:

• New combinations (e.g., with radiotherapy, chemotherapy, or targeted agents in oncology)
• Comparative pharmacokinetic or formulation studies (rarely changing the core safety/efficacy profile)
• Real-world/registry studies (often observational, not interventional)

The key commercial reality: Zoladex is a mature asset. Trial pipelines in public databases typically do not drive new market share at scale unless a region-specific study enables label expansion, pricing leverage, or supply continuity.

Practical implications for R&D and contracting

• Near-term growth is more likely to come from channel execution and reimbursement, not from new clinical readouts.
• Competitive intensity usually shifts through tendering and comparative price of competing GnRH agonists or oral alternatives (where clinically appropriate).

---

How does Zoladex fit the competitive landscape?

Zoladex competes in the GnRH agonist implant segment and broader hormone-sensitive oncology space. Competitor classes include:

• Other long-acting GnRH agonists (injectable depots or implants)
• GnRH antagonists in prostate and breast oncology settings where clinically adopted
• Surgical and radiotherapeutic alternatives in certain disease states

Commercial dynamic: In hormone-sensitive indications, switching is often constrained by:

• clinician familiarity with depot timing and tolerability
• patient experience with injection intervals
• payer formularies and tender rules
• consistent supply availability

---

What is the market analysis for Zoladex?

Market drivers

1. Incidence base: prostate cancer incidence is structurally supported by aging populations; breast cancer incidence supports demand for hormone modulation in eligible populations.
2. Treatment adherence: long-acting implants simplify adherence versus more frequent regimens.
3. Formulary entrenchment: established place in therapy reduces switching friction.
4. Pricing and procurement: major markets use national tender and centralized purchasing, where continuity of supply is a decisive factor.

Key market constraints

• Patent and exclusivity status affects pricing power depending on jurisdiction.
• GnRH antagonist adoption can substitute in some oncology pathways and settings.
• Biosimilar or competing depot products can pressure net pricing.

Net result: Zoladex behaves like a mature chronic-use oncology and women’s health product with growth linked to population trends and procurement outcomes rather than breakthrough uptake.

---

What does market projection indicate through 2035?

A credible projection for a mature, off-patent asset requires anchor variables: incidence/diagnosis volume, persistence, tender pricing, and competitive substitution. Without jurisdiction-specific sales time series, the projection should be framed as a directional expectation by geography and segment.

Projection framework (directional)

• Volume: modest growth in underlying eligible patient pools in major markets, tempered by therapy substitution in oncology.
• Value: flat to low-single-digit CAGR in many markets due to pricing pressure from generics, competitors, and tendering.
• Share: stable where supply continuity and formulary position remain intact; softening where GnRH antagonists or alternative regimens gain adoption.

Base-case expectation (2024-2035)

• Revenue trajectory: low-growth, tender-sensitive market behavior.
• Share trajectory: stable to slight erosion in segments where antagonists are preferred and where payer formularies steer switching.
• Segment behavior: prostate cancer remains the largest anchor; women’s health indications remain more policy and reimbursement dependent.

---

What clinical endpoints and label mechanics matter most commercially?

For long-acting GnRH agonists, payer and clinician decisions often hinge on:

• Dosing interval compatibility (3.6 mg monthly vs 10.8 mg every 12 weeks)
• Safety profile stability (class effects: flare risk, hot flashes, bone density considerations)
• Disease-specific response expectations (hormone suppression)
• Switching rules under local clinical guidelines

Commercially, these translate into contracting logic:

• products that reduce injection frequency often win adherence-related formulary preference where budgets allow
• products that meet tender specifications and maintain supply continuity tend to retain share even if a lower-priced competitor exists

---

Where are the key practical watchpoints?

1. Tender and reimbursement cycles: procurement outcomes can change net pricing materially even when brand-level demand stays stable.
2. Oncology guideline updates: preferences toward GnRH antagonists where adopted can reduce GnRH agonist share in prostate and some breast pathways.
3. Supply chain risk: depot products require stable manufacturing and distribution; disruptions translate quickly into tender reallocation.
4. Real-world persistence: depot adherence and discontinuation rates influence volume more than incremental efficacy claims at this stage.

---

Key Takeaways

• Zoladex is a mature long-acting GnRH agonist with demand anchored by hormone-sensitive oncology and selected women’s health indications.
• Public clinical trial activity is limited and typically does not reset the clinical profile at scale; competitive advantage relies more on procurement, supply continuity, and formulary position than new phase programs.
• Market growth through 2035 is expected to be low and tender-driven, with stable-to-slight share erosion where GnRH antagonists and alternative regimens gain guideline and payer preference.
• The core business lever is channel and contracting: pricing, tender specifications, and consistent implant supply drive net performance.

---

FAQs

1. Is Zoladex still actively developed in late-stage trials?
   Public interventional activity appears limited relative to newer biologics and small-molecule oncology programs, consistent with a mature asset and entrenched label use.

2. What drives Zoladex demand in prostate cancer?
   Eligible patient volume plus persistence under long-acting dosing schedules, modulated by payer and guideline preferences versus GnRH antagonists.

3. Does Zoladex compete mainly with other GnRH agonists or antagonists?
   It competes with both, but substitution risk is highest where GnRH antagonists are favored in payer formularies and clinical guidelines.

4. Why do dosing interval options matter commercially?
   Every-12-week regimens can improve convenience and adherence, which can support formulary preference and reduce patient friction, especially under tendering constraints.

5. What is the biggest risk to long-term revenue growth?
   Net price compression from tendering and competitive substitution in oncology pathways where class alternatives are preferred.

---

References

[1] European Medicines Agency. (n.d.). Zoladex (goserelin) product information and EPAR resources. https://www.ema.europa.eu/
[2] U.S. Food and Drug Administration. (n.d.). Zoladex (goserelin) prescribing information. https://www.accessdata.fda.gov/
[3] ClinicalTrials.gov. (n.d.). Zoladex (goserelin) clinical studies database. https://clinicaltrials.gov/